TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: accuracy of the NICE criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sequential Organ Failure Assessment (SOFA) score evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-invasive Tear Break up Time (TBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject-reported number of swollen joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Subject-reported time to resolution of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methacholine Challenge Test Result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety profile of cetuximab
Endpoint domain: Adverse events/effects
Primary endpoint: Change in level of calcium, cholesterol status, haemoglobin, magnesium, sodium, potassium in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in level of HbA1c in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in level of Thyroid Stimulating Hormone (TSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak isokinetic eccentric hamstring strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Perceived Ease of Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: System Usability
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Body mass (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of IL-6 (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels and mutations of circulating exosome RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Global Success Rating (GSR)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Separation Anxiety Inventory for Children (SAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with any Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with fatal Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: hypolipidemic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dark halo measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAE)s
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-emergent Serious Adverse Events (TESAE)s
Endpoint domain: Adverse events/effects
Primary endpoint: Prescription for triptan
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Blood donation rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Device monitored adherence rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: program evaluation and acceptability rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diarrhea severity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the average proportion of observed SCC tasks completed per birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five-point surgical rating scale (SRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prescription Analgesic Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: occurrence of post procedure infectious complications
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective voice evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Achilles tendon Total Rupture Score (ATRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance and expansion of tissue repositories
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Local common carotid artery pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Pain Severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hemoglobin target achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Phosphate target achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Myofibrillar Fractional Synthetic Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of non-smokers at 4 weeks and six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of skin plastoelasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Seroconversion after hepatitis A vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: persistent control of virus replication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to NSCs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan
Endpoint domain: Adverse events/effects
Primary endpoint: Change in number of unfulfilled health care goals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Rebound Hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence to oral therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ALOX5 mRNA and protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Arachidonic acid-derived leukotrienes levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of cut-out failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative pain degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Condom Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall Incidence of Risk Behaviors Associated with HIV/STI Transmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in the Average AM Instantaneous Total Nasal Symptom Score (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Average AM Instantaneous Total Ocular Symptom Score (TOSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of High Glucose Correction Doses Administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nailfold microcirculation morphological integral
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nailfold microcirculation blood flow integral
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nail fold microcirculation perivascular loop integral
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Rank Composite Score (GRCS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: serum neutrophil-gelatinase-associated lipocalin (NGAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Event Rate of Stroke/Systemic Embolism Requiring Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Event Rate of Major Bleeding Requiring Hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of local therapy completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Expressed intent to participate in a CRSP program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Toxicities of the combination treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Improved Participants on the GAIS-Subject
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Improved Participants on the GAIS-Investigator
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peak expiratory flow correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak inspiratory flow correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventilation/local time constant correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Geometric mean titers (GMTs) of hemagglutination inhibition (HI) antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion Rates (SCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection Rates (SPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Occurrence of Bacteriuric Urinary Tract Infection (bUTI)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in logMAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year Disease-Free Rate (DFR)
Endpoint domain: Mortality/survival
Primary endpoint: 2-year Disease-Free Rate (DFR)
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in HIV plasma viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adherence to gluten-free diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oxidative stress in the umbilical artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global PSQI Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Hand function assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual Acuity - Right Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity - Left Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subclinical Atherosclerotic Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Likelihood ratio of urinary calcium δ44/40 Ca values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in peak velocity during Instrumented Stand and Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event rates and severity
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma nitrate (NOx) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's Global Assessment (Blinded)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of positive COVID-19 women
Endpoint domain: Mortality/survival
Primary endpoint: Clinical laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK linearity of CHF 6532
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady state PK of CHF 6532
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cessation of leakage from choroidal neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Changes in WOMAC Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in maternal hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fasting plasma lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency and severity of vaccine-related adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of dengue 2 neutralizing antibody induced by the vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Confirmed Response (Complete Response, Very Good Partial Response, Partial Response, or Minimal Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Length of Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Post operative endodontic's pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nerve ending number measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes of Mini-Mental State Examination (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes of Instrumental Activities of Daily Living (IADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes of Geriatric Depression Scale (GDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual acuity (ETDRS scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of the layers of the retina with Optical Coherent Tomography (OCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Humphrey Visual Field Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With an Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cumulative incidence of skin and soft tissue infection
Endpoint domain: Adverse events/effects
Primary endpoint: Target Limb Revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Parental Stress Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in diabetes quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction of breathlessness intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: T-Cell Receptor/B-Cell Receptor gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Achieving Maintenance Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiopulmonary Exercise Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: oxidative damage markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: AUC and Cmax of SB-751689, rosuvastatin, and atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in cerebral blood flow velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Interaction between care path and life course
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient and family coping with disease
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in monthly income
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Combined Complete Response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Determination of GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to Reach Maximum Observed Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Nervous System (CNS) Objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Surgical Site Infection (proportion)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peripheral Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of subjects having at least 6 months of seizure freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Percentage of subjects having at least 6 months of seizure freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Thienopyridine resistance prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive value of HPV E6/E7 mRNA for HSIL detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with COVID-19-negative PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: iOS measurements of reactance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability (Adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Change of dystrophin expression rate in muscle tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall knowledge of prematurity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Subjects With Drug-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Sugar Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participant Response to Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume Difference of Malformation to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume Difference of the Affected Extremity to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed of onset of motor blockage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time of recovery of motor blockage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: amount of oral analgesic used post procedure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: HCC recurrence free survival
Endpoint domain: Mortality/survival
Primary endpoint: Branched-chain Amino Acid Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accumulated duration of self-assessed sick leave due to LBP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Classification of the patient as a responder or a non responder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptation and Action Questionnaire - II (AAQ-II) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rates of acute grade 3 or higher radiotherapy toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Gait comfortable speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Venom Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of enrolled patients completing at least 3 symptom surveys
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients completing the exit survey
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients who return the phone
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: uNGF level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to pain free full weight bearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of low dose CT for detection of urinary tract stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: First episode of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Restoration of coronary blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient Tolerance of Conivaptan
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Processing Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Major Complication Rate
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of survival
Endpoint domain: Mortality/survival
Primary endpoint: Changes in bone mineral density of the lumbar spine (L2-L4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood Pressure Referral Threshold Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in brain microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Substance Exposed Pregnancy (SEP) risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes